Jason Luke, MD, FACP, discusses key takeaways from the KEYNOTE-716 and KEYNOTE-942 trials and other key updates from across the melanoma landscape presented at the 2023 ASCO Annual Meeting.
Clinical Trials
Opdivo, Opdualag Still Benefits Patients With Melanoma at 2 Years
After two years of follow-up, patients with advanced melanoma treated with Opdivo and Opdualag continued to obtain a survival benefit compared with Opdivo alone.
Trial Will Evaluate Frontline Treatment With Lifileucel in Melanoma
The TILVANCE-301trial, expected to be completed in 2030, is the latest study of what has been described as one of the “phenomenal discoveries in melanoma.”
Camrelizumab Plus Famitinib Demonstrates Early Antitumor Activity in Advanced Melanoma
Camrelizumab combined with famitinib elicited responses and was well tolerated in patients with advanced melanoma previously exposed to an immune checkpoint inhibitor regimen.